DK2478905T3 - Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler - Google Patents

Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler

Info

Publication number
DK2478905T3
DK2478905T3 DK12160638.8T DK12160638T DK2478905T3 DK 2478905 T3 DK2478905 T3 DK 2478905T3 DK 12160638 T DK12160638 T DK 12160638T DK 2478905 T3 DK2478905 T3 DK 2478905T3
Authority
DK
Denmark
Prior art keywords
carbonitrils
aminoquinolin
imatinib
treatment
resistant leukemia
Prior art date
Application number
DK12160638.8T
Other languages
Danish (da)
English (en)
Inventor
Becker Hewes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2478905(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK2478905T3 publication Critical patent/DK2478905T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK12160638.8T 2007-06-01 2008-05-30 Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler DK2478905T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
EP08769857A EP2152267A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number Publication Date
DK2478905T3 true DK2478905T3 (da) 2014-06-30

Family

ID=39639071

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12160638.8T DK2478905T3 (da) 2007-06-01 2008-05-30 Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
DK15191756.4T DK3002009T3 (da) 2007-06-01 2008-05-30 Behandling af imatinib-resistent kronisk myeloid leukæmi, som har mutationen 1457t>c i bcrabl-genet, under anvendelse af forbindelsen bosutinib

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15191756.4T DK3002009T3 (da) 2007-06-01 2008-05-30 Behandling af imatinib-resistent kronisk myeloid leukæmi, som har mutationen 1457t>c i bcrabl-genet, under anvendelse af forbindelsen bosutinib

Country Status (23)

Country Link
US (1) US11103497B2 (https=)
EP (4) EP2152267A2 (https=)
JP (3) JP5888853B2 (https=)
KR (1) KR101493543B1 (https=)
CN (1) CN101686973B (https=)
AU (1) AU2008260070B9 (https=)
BR (1) BRPI0812355A2 (https=)
CA (3) CA2964162C (https=)
CL (1) CL2008001577A1 (https=)
CY (2) CY1115251T1 (https=)
DK (2) DK2478905T3 (https=)
ES (2) ES2881391T3 (https=)
HU (1) HUE055524T2 (https=)
IL (1) IL202407A0 (https=)
MX (1) MX2009013069A (https=)
PA (1) PA8782301A1 (https=)
PL (2) PL2478905T3 (https=)
PT (2) PT2478905E (https=)
RU (1) RU2464026C2 (https=)
SI (2) SI3002009T1 (https=)
TW (1) TW200908982A (https=)
WO (1) WO2008150957A2 (https=)
ZA (1) ZA200908480B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055524T2 (hu) 2007-06-01 2021-11-29 Wyeth Llc A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基-喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CA2902132C (en) 2013-02-21 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
US20220388962A1 (en) * 2019-08-22 2022-12-08 Biohaven Therapeutics Ltd. Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
PT2017335E (pt) 2001-10-05 2011-03-02 Novartis Ag Domínios da cinase abl mutados
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
RU2387653C2 (ru) * 2005-05-16 2010-04-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
EP1904654A2 (en) 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
WO2007056177A2 (en) 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
HUE055524T2 (hu) * 2007-06-01 2021-11-29 Wyeth Llc A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával

Also Published As

Publication number Publication date
US11103497B2 (en) 2021-08-31
EP3002009A3 (en) 2016-07-06
JP5888853B2 (ja) 2016-03-22
JP2010529038A (ja) 2010-08-26
CN101686973B (zh) 2013-06-19
WO2008150957A3 (en) 2009-08-06
CY1124391T1 (el) 2022-07-22
AU2008260070B2 (en) 2011-08-18
EP2478905A2 (en) 2012-07-25
HUE055524T2 (hu) 2021-11-29
IL202407A0 (en) 2010-06-30
KR101493543B1 (ko) 2015-02-13
EP2478905A3 (en) 2013-01-16
ES2477567T3 (es) 2014-07-17
CA2964162C (en) 2019-12-31
CY1115251T1 (el) 2017-01-04
JP2014111629A (ja) 2014-06-19
CA2868899A1 (en) 2008-12-11
EP3002009A2 (en) 2016-04-06
EP2777704A3 (en) 2015-01-21
PA8782301A1 (es) 2009-01-23
RU2464026C2 (ru) 2012-10-20
ZA200908480B (en) 2010-08-25
US20080318971A1 (en) 2008-12-25
KR20100017983A (ko) 2010-02-16
WO2008150957A2 (en) 2008-12-11
EP2152267A2 (en) 2010-02-17
MX2009013069A (es) 2010-03-17
EP2777704A2 (en) 2014-09-17
HK1142812A1 (en) 2010-12-17
EP3002009B1 (en) 2021-07-07
ES2881391T3 (es) 2021-11-29
BRPI0812355A2 (pt) 2015-01-27
CA2868899C (en) 2017-06-13
CA2964162A1 (en) 2008-12-11
JP2016074700A (ja) 2016-05-12
CL2008001577A1 (es) 2008-07-25
CA2688467A1 (en) 2008-12-11
PL2478905T3 (pl) 2014-10-31
SI2478905T1 (sl) 2014-07-31
SI3002009T1 (sl) 2021-09-30
EP2478905B1 (en) 2014-05-14
RU2009144128A (ru) 2011-07-20
DK3002009T3 (da) 2021-08-02
PT2478905E (pt) 2014-07-16
TW200908982A (en) 2009-03-01
AU2008260070A1 (en) 2008-12-11
CA2688467C (en) 2015-05-12
CN101686973A (zh) 2010-03-31
PL3002009T3 (pl) 2021-12-13
PT3002009T (pt) 2021-08-02
AU2008260070B9 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK2478905T3 (da) Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2350116T3 (da) Behandling af biofilm
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2144923T3 (da) Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
BRPI0812803A2 (pt) Dessalinização
DE602008003015D1 (de) Heterocyclische spiroverbindungen
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2173831T3 (da) Brøndbehandling
DE112008002921A5 (de) Bohrfutter
DK2175849T3 (da) Behandling af melanomer
DK2181065T3 (da) Partialoxidation af carbonhydrider
DK2118174T3 (da) Anvendelse af tocopherol
DE102007047112A8 (de) Strahlregler
DE502008000590D1 (de) Einstellvorrichtung
ATE506032T1 (de) Endoprothesenkomponente
DK3388111T3 (da) Organoarsenforbindelse til behandlingen af kræft
BRPI0817439A2 (pt) gaseificador